Side-by-side comparison of AI visibility scores, market position, and capabilities
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Rebranded to Veradigm Jan 2023; $620-635M revenue expected 2024; 180K+ physician users; 3.6% ambulatory EHR market share; sold hospital business to Harris Computer $700M 2022; Nasdaq suspended Feb 2024
Allscripts is a healthcare IT company founded in 1986 in Chicago, historically one of the largest providers of electronic health record and practice management software for physician practices and hospitals in the United States. The company rebranded to Veradigm in January 2023, signaling a strategic pivot from legacy EHR software toward data analytics, life sciences research enablement, and healthcare network intelligence — areas where its 180,000+ physician user base and de-identified patient data assets create differentiated value for pharmaceutical and payer customers.\n\nThe Veradigm platform combines its ambulatory EHR and practice management software with a data and analytics layer that aggregates real-world clinical data for life sciences research, post-market drug surveillance, and population health analytics. Its network of physician practices represents one of the largest ambulatory data footprints in the US, making Veradigm a valuable partner for pharmaceutical companies seeking real-world evidence and patient registries. The company maintains a 3.6% share of the ambulatory EHR market while building out higher-margin analytics and data licensing revenue streams.\n\nVeradigm (formerly Allscripts) targets $620–635M in revenue for 2024, serving 180,000+ physician users across its installed EHR base. The rebrand to Veradigm reflects management's intent to migrate the business model from competitive, commoditizing EHR software toward network and data platform economics. As life sciences companies increase investment in real-world evidence and physicians demand more integrated practice intelligence tools, Veradigm's combination of clinical workflow reach and data network assets gives it a credible platform for this strategic repositioning.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.